Skip to main
  1. Stocks
  2. PDS Biotechnology Corporation
  3. Forecast
PDSB

PDSB Stock Forecast & Price Target

PDSB Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PDS Biotechnology is viewed favorably because its lead asset PDS0301 has shown durable and differentiated activity in a difficult MSS/pMMR mCRC liver-metastases setting, including a 6-month ORR advantage, 3 complete responses, and a published OS hazard ratio of 0.30 versus a challenging benchmark. The outlook is further supported by the company’s strategic refocus on PDS0301, which concentrates resources on a broader tumor-localized IL-12 approach while reducing spending on VERSATILE-003 and lowering R&D and G&A after the ~36% workforce reduction and $842K restructuring charge in 3Q26. Financial risk also improved after the up to $22.55M Nant-led PIPE, which followed a 2Q26 cash balance of $5.6M and helped fund the planned Phase 3 submission while reducing, though not eliminating, the financing overhang.

Bears say

PDS Biotechnology is burdened by a weak risk/reward profile because its lead PDS0301 liver-met dataset is nonrandomized, small at 22 patients versus a 20-patient sequential comparator, and the promised 6-month ORR and survival signals may not replicate in a multi-center Ph3 with mature survival data still pending. Regulatory and execution uncertainty are equally severe: the Ph3 design has not yet been accepted by FDA, approval or reimbursement is uncertain, and the regimen relies on hepatic artery pump placement, enrollment pace, and toxicity control that may differ from the NCI experience. Financing is the key gating factor, as the company cannot fund the Ph3 from cash in hand, needs about $15M for the randomized mCRC study and another $15M for operations through the interim analysis, and may face dilution or going-concern risk given the committed $11M milestone closing and sub-$2 share price.

PDSB has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PDS Biotechnology Corporation and is not a guaranteed prediction by Public.com or investment advice.

PDSB Analyst Forecast & Price Prediction

Get the latest PDSB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PDSB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PDS Biotechnology Corporation (PDSB) Forecast

Analysts have given PDSB a Strong Buy based on their latest research and market trends.

According to 2 analysts, PDSB has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PDS Biotechnology Corporation (PDSB)


PDSB Analyst Forecast & Price Prediction

Get the latest PDSB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PDSB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PDSB stock data and trends